[
    {
        "pregunta": "1. How does the quality of evidence (high, moderate, low, very low) impact vaccination recommendations in patients with RMD?",
        "respuesta": "La calidad de la evidencia (alta, moderada, baja, muy baja) influye directamente en el nivel y la fortaleza de las recomendaciones de vacunación para pacientes con enfermedades reumáticas y musculoesqueléticas (ERM). Por ejemplo, en la revisión sistemática realizada sobre inmunogenicidad y eficacia de vacunas (como la influenza) en pacientes con ERM, se encontró que la calidad de evidencia a menudo es baja o muy baja, lo que implica que nuevas investigaciones podrían cambiar las conclusiones actuales.\n\nEn este contexto:\n\n- Las recomendaciones se basan no solo en la evidencia disponible, sino también en el equilibrio entre beneficios y riesgos, y en las preferencias y valores de los pacientes.\n- Cuando la calidad de la evidencia es baja o muy baja, las recomendaciones tienden a ser condicionales o sujetas a cambios, destacando la necesidad de compartir la toma de decisiones con el paciente.\n- En casos donde la evidencia es moderada o alta, las recomendaciones pueden ser más firmes.\n\nEn resumen, la baja calidad o incertidumbre de la evidencia limita el grado de certeza con que se puede realizar una recomendación fuerte sobre vacunación en pacientes con ERM, promoviendo un enfoque individualizado y compartido en la decisión clínica.",
        "contexto": [
            "influenza vaccination, recombinant VZV vaccination, and primary and booster COVID-19 vaccination in RMD patients taking immunosuppressive medication; and 4) RCTs to test the safety and efficacy of holding DMARDs around the time of vaccination.  † The terms 'moderate', 'low', and 'very low' are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) definitions for quality of evidence. Moderate quality means that \"further research is likely to have an important",
            "| <strong>Whether to defer vaccination in patients with high disease activity to maximize vaccine immunogenicity and/or avoid worsening disease activity</strong> | <strong>Very low</strong>                                     | PICO 13. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients who have moderate to severely active underlying disease as compared to those in low disease activity or remission? | 737–739                  |",
            "the quality of the evidence was low. Strong concerns, however, were expressed among the Patient Panel about the potential for vaccines to cause a disease flare, and shared decision-making is particularly important in this setting. Most studies suggest that increased disease activity does not impact vaccine immunogenicity Managing immunosuppressive therapy at the time of live attenuated vaccination to avoid vaccine-associated illness (Table 5 For patients with RMD who are taking",
            "recommendations indicate that clinicians should engage in shared decision-making with patients when deciding whether to use these interventions. The low or very low certainty evidence supporting most recommendations calls for prioritizing research into these interventions and prompted a proposed research agenda (Table 7 There are limitations to the development of these guidelines. Studies that were conducted prior to more recent treatment eras (characterized by early diagnosis of RA and a",
            "confidence in the evidence based on the lowest quality of the critical outcomeshigh, moderate, low, or very low), and patients' values and preferences. The rating of the quality of evidence for each clinical situation (PICO question) helped to inform the strength of the recommendation (strong or conditional) The use of GRADE (not used in other PsA treatment recommendations) allowed an explicit consideration of the overall evidence, including the balance of benefits and harms of treatments, the"
        ]
    },
    {
        "pregunta": "2. How should immunosuppressive medications other than methotrexate and rituximab be managed around the time of non-live attenuated vaccine administration?",
        "respuesta": "El manejo de medicamentos inmunosupresores distintos a metotrexato y rituximab alrededor del momento de la administración de vacunas no vivas atenuadas, según la guía, es que **se recomienda continuar el uso de estos medicamentos durante la vacunación**. \n\nNo se sugiere suspender ni modificar la dosis de estos inmunosupresores en el momento de administrar vacunas no vivas atenuadas, ya que la evidencia para indicar lo contrario es insuficiente y las recomendaciones al respecto son condicionales.\n\nEn resumen:  \n- **Medicamentos inmunosupresores distintos a metotrexato y rituximab:** continuar tratamiento alrededor del momento de vacunación con vacunas no vivas atenuadas.  \n- Las recomendaciones son condicionales debido a la baja calidad de la evidencia y la falta de estudios específicos.  \n- Se enfatiza la importancia de la toma de decisiones compartida entre médico y paciente.\n\nEsta estrategia busca mantener el control adecuado de la enfermedad reumática sin interrumpir el tratamiento inmunosupresor innecesariamente durante la vacunación.",
        "contexto": [
            "around the time of influenza vaccination is conditionally recommended. For patients with RMD, continuing immunosuppressive medications around the time of other (non-influenza) nonlive attenuated vaccinations is conditionally recommended. Many observational studies The literature review identified no studies that directly addressed the impact of holding medications other than methotrexate at the time of influenza vaccination. Two RCTs performed in patients initiating TNFi versus placebo",
            "to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the recommendations are conditional and apply across diseases, vaccines, medications, and age groups. Because of the low quality of the evidence, shared decision-making between clinicians and patients/parents/guardians is particularly important for the vaccination",
            "<p>|Immunosuppressive medication|Hold before live-attenuated virus vaccine administration|Hold after live-attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoidsᵃ|4 weeks|4 weeks|\n|Methotrexate, azathioprineᵇ|4 weeks|4 weeks|\n|Leflunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL17, IL12/23, IL23, BAFF/BLyS inhibitors|1 dosing intervalᶜ|4 weeks|",
            "attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended. Influenza vaccine responses are greater when the vaccine is administered later rather than earlier after rituximab Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or with active disease (Table 4 Glucocorticoids Whether to administer non-live attenuated",
            "<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Methotrexate|Hold methotrexate for 2 weeks after vaccination<em>|Continue methotrexate|\n|Rituximab|Continue rituximab</em>*|Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination|\n|Immunosuppressive medications other than methotrexate and rituximab|Continue immunosuppressive medication|Continue immunosuppressive medication|</p>"
        ]
    },
    {
        "pregunta": "3. What is the rationale for holding IVIG prior to vaccination?",
        "respuesta": "La justificación para suspender la administración de inmunoglobulina intravenosa (IVIG) antes de la vacunación es **mejorar la eficacia de la vacuna**, no por razones de seguridad. Los anticuerpos antivirales presentes en la IVIG pueden interferir con la replicación de las vacunas vivas atenuadas, reduciendo así la respuesta inmunitaria y la efectividad de la vacunación. Por ello, se recomienda evitar la administración de IVIG en un periodo previo a la vacunación para optimizar la respuesta inmunológica.  \n\nSin embargo, en situaciones específicas, como durante un brote de sarampión, se puede priorizar vacunar antes y no retrasar la vacunación, a pesar de la administración reciente de IVIG.",
        "contexto": [
            "<h1>The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efﬁcacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</h1>\n\n<h1>Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*</h1>",
            "held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero",
            "<p>d. In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical.</p>\n\n<p>e. the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</p>",
            "the study participant lacked prevaccination immunity to VZV Intravenous immunoglobulin (IVIG). Antiviral antibodies contained in IVIG can interfere with replication of live attenuated vaccines and reduce their efficacy Specific recommendations for holding medications if live attenuated vaccines are given. Although the evidence around the safety of conventional DMARDs and TNFi at the time of live attenuated virus vaccination is reassuring, the total number of RMD patients who have been studied",
            "to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the recommendations are conditional and apply across diseases, vaccines, medications, and age groups. Because of the low quality of the evidence, shared decision-making between clinicians and patients/parents/guardians is particularly important for the vaccination"
        ]
    },
    {
        "pregunta": "4. What is the evidence quality regarding holding immunosuppressive medications to improve vaccine response?",
        "respuesta": "La calidad de la evidencia respecto a suspender medicamentos inmunosupresores para mejorar la respuesta a la vacunación en pacientes con enfermedades reumáticas y musculoesqueléticas (ERM) es **baja o muy baja en la mayoría de las comparaciones**, con algunas evaluaciones de calidad moderada para ciertos medicamentos o vacunas.  \n\nEn concreto:  \n- No hay estudios concluyentes ni específicos que permitan recomendar firmemente la suspensión de inmunosupresores para maximizar la inmunogenicidad de la vacunación.  \n- Por lo tanto, las recomendaciones al respecto son **condicionales** y se basan en evidencia limitada.  \n- Además, suspender medicamentos podría aumentar el riesgo de recurrencia o flare de la enfermedad, lo que debe sopesarse en la toma de decisiones.  \n- Por esta razón, se enfatiza la importancia de una toma de decisiones compartida entre clínicos y pacientes, adaptada al caso particular.\n\nEn resumen, la evidencia actual no es suficiente ni robusta para recomendar la suspensión sistemática de inmunosupresores con el fin de mejorar la respuesta a la vacunación.",
        "contexto": [
            "to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the recommendations are conditional and apply across diseases, vaccines, medications, and age groups. Because of the low quality of the evidence, shared decision-making between clinicians and patients/parents/guardians is particularly important for the vaccination",
            "| <strong>Whether to hold immunosuppressive medication at the time of non–live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550",
            "| <strong>For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |",
            "| <strong>PICO 15</strong>                                                                           | <strong>TNFi: low; tocilizumab: very low; secukinumab: very low; tofacitinib: moderate; glucocorticoids: very low; abatacept: very low</strong> | PICO 15. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking drug Y as compared to those not taking drug Y at the time of vaccination? | 754–898                  |",
            "the quality of the evidence was low. Strong concerns, however, were expressed among the Patient Panel about the potential for vaccines to cause a disease flare, and shared decision-making is particularly important in this setting. Most studies suggest that increased disease activity does not impact vaccine immunogenicity Managing immunosuppressive therapy at the time of live attenuated vaccination to avoid vaccine-associated illness (Table 5 For patients with RMD who are taking"
        ]
    },
    {
        "pregunta": "5. In children with systemic juvenile idiopathic arthritis, when can shorter hold times for biologic DMARDs be considered?",
        "respuesta": "En niños con artritis idiopática juvenil sistémica (sJIA) o trastornos autoinflamatorios, **se pueden considerar periodos de suspensión más cortos de medicamentos biológicos modificadores de la enfermedad (biológicos DMARDs) cuando el riesgo de brote de la enfermedad es muy alto y la vacunación con vacuna viva atenuada es crítica**.  \n\nEsta consideración se basa en evitar la interrupción prolongada del tratamiento inmunomodulador en situaciones donde el control de la enfermedad es prioritario, ajustando el tiempo de suspensión para permitir la vacunación urgente sin aumentar demasiado el riesgo de reactivación.\n\n**En resumen:**  \n- Suspensiones más cortas de biológicos DMARDs son una opción en pacientes pediátricos con sJIA o autoinflamatorios con alto riesgo de brote y que requieren vacunación con vacuna viva atenuada crítica.  \n- La decisión debe balancear el riesgo de flare grave frente a la necesidad de inmunización.  \n\nNo se especifican en la información los tiempos exactos para estos periodos cortos de suspensión.",
        "contexto": [
            "<p>¶ In children with autoinﬂammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic disease-modifying antirheumatic drugs are held is very high, shorter hold times can be considered if live attenuated vaccination is critical.</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "of efficacy or poor tolerability is appropriate. Concerns were expressed regarding a highly fatal lung disease observed in some children with systemic JIA, most of whom were treated with bDMARDs. Observed risk factors include younger age with MAS, a history of reactions to tocilizumab, and trisomy 21 NSAIDs NSAIDs are conditionally recommended as initial monotherapy for systemic JIA without MAS. Studies suggest that a small proportion of patients with systemic JIA will respond to NSAIDs alone",
            "|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|\n|There is no preferred biologic DMARD.| | | |",
            "|Tapering and discontinuing biologic DMARDs is conditionally recommended after inactive disease has been attained.|Very low|PICO 29. In patients with systemic JIA in clinical remission with biologic monotherapy, is tapering by decreasing dosage superior to tapering dosing interval at preventing disease exacerbation, preventing development of antidrug antibodies, and minimizing medication toxicity?|140–143|</p>"
        ]
    },
    {
        "pregunta": "6. What are tsDMARDs and which vaccines are considered safe or not safe to administer in patients treated with these drugs?",
        "respuesta": "La información proporcionada **no incluye una definición específica de los tsDMARDs (fármacos modificadores de la enfermedad dirigidos, orales)** ni detalla qué vacunas se consideran seguras o inseguras para administrar en pacientes tratados con estos medicamentos.\n\nPor lo tanto, **no es posible proporcionar una respuesta basada en la evidencia disponible** sobre qué vacunas son seguras o no en pacientes tratados con tsDMARDs ni describir con precisión qué son estos fármacos según la información presentada.\n\nSe sugiere consultar guías específicas de vacunación en pacientes con enfermedades reumáticas bajo tratamiento con tsDMARDs para obtener recomendaciones basadas en evidencia actualizada.",
        "contexto": [
            "of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy This conditional recommendation is made based on observational data suggesting a lower risk of infection associated with combination csDMARDs (dual or triple therapy) compared to bDMARDs or tsDMARDs Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a",
            "a bDMARD or tsD-MARD is typically added following an inadequate response to methotrexate. Thus, the continued use of the bDMARD or tsDMARD is more likely to maintain disease control than the continued use of methotrexate. The recommendation is conditional because gradual discontinuation of the bDMARD or tsDMARD may be favored depending on comorbidities, risk for infection, cost concerns, as well as patient and clinician preferences. The voting panel cautioned that many patients treated with",
            "|Previous serious infection| | | |\n|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 88|p. 490|",
            "| What is the efficacy of TTT in different patient populations (early versus late, bDMARD-or tsDMARD-exposed, elderly-onset, comorbidities)?                                      |\n| What is the optimal target and method of assessment of disease activity for TTT in different populations?                                                                        |</p>",
            "DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be"
        ]
    },
    {
        "pregunta": "7. What are the general recommendations regarding the use of high-dose or adjuvanted influenza vaccines in patients with RMD?",
        "respuesta": "Las recomendaciones generales sobre el uso de vacunas de influenza de alta dosis o con adyuvantes en pacientes con enfermedades reumáticas y musculoesqueléticas (ERM) son las siguientes:\n\n- Para pacientes con ERM **de 65 años o más**, y para pacientes con ERM **mayores de 18 y menores de 65 años que estén recibiendo medicación inmunosupresora**, se recomienda **condicionalmente** el uso de la vacuna de influenza de alta dosis o con adyuvantes en lugar de la vacuna de dosis estándar.\n\n- Estas vacunas contienen una mayor cantidad de antígeno (cuadrivalentes con 4 veces el antígeno de la vacuna estándar) y demostraron en ensayos clínicos controlados en pacientes con artritis reumatoide tasas mayores de seroconversión, sin señales de seguridad adversa relevante.\n\n- No existen restricciones claras para administrar estas vacunas a pacientes menores de 65 años, pero su uso preferente es para los grupos mencionados.\n\nEn resumen, el panel favorece la vacunación con la vacuna de influenza de alta dosis o con adyuvantes en pacientes con ERM mayores de 65 años y en adultos inmunosuprimidos menores de 65 años, buscando mejorar la respuesta inmunitaria y fomentar la adhesión a la vacunación.",
        "contexto": [
            "regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no",
            "restrictions may preclude administration of high-dose or adjuvanted influenza vaccination to patients <65 years of age. High-dose influenza vaccine is a quadrivalent vaccine containing 4 times the antigen as the standard-dose vaccine. Two RCTs in rheumatoid arthritis (RA) patients showed higher seroconversion rates in younger patients receiving high-dose vaccination compared to standard-dose vaccination with no safety signal Pneumococcal vaccination For patients with RMD age <65 years who are",
            "if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology.",
            "2) this guideline is complementary to recommendations from the ACIP RESULTS/RECOMMENDATIONS Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination For patients with RMD age ≥65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. Any influenza vaccine is",
            "Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal"
        ]
    },
    {
        "pregunta": "8. Under what circumstances should seasonal influenza vaccination be administered to RMD patients, even if disease activity is high or patients are on high-dose glucocorticoids or rituximab?",
        "respuesta": "La vacunación estacional contra la influenza **debe administrarse a pacientes con enfermedades reumáticas y musculoesqueléticas (ERM) incluso si la actividad de la enfermedad es alta, si están recibiendo dosis elevadas de glucocorticoides y/o están en tratamiento con rituximab**. \n\nEsta recomendación es condicional y se basa en la evidencia que indica que la infección por influenza puede ser especialmente grave en esta población, y que la vacuna es segura y beneficiosa independientemente del estado inflamatorio o del uso de glucocorticoides o rituximab.\n\nEn resumen:\n- La vacuna antigripal se debe administrar **en cualquier momento de la temporada, sin posponerla por la actividad alta de la ERM**.\n- En pacientes bajo tratamiento con rituximab, se recomienda administrar la vacuna antigripal según el calendario habitual, sin necesidad de diferirla hasta el siguiente ciclo de rituximab.\n- Si la enfermedad lo permite, es recomendable retrasar la siguiente dosis de rituximab al menos 2 semanas después de la vacunación para optimizar la respuesta, pero la vacunación no debe omitirse ni retrasarse.\n\nEsta estrategia busca maximizar la protección contra la influenza en pacientes con ERM, minimizando el riesgo de infecciones graves.",
        "contexto": [
            "if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology.",
            "regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no",
            "| For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due. |                                                  |                                                                                                                      |                          |",
            "<ul>\n<li>Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</li>\n</ul>\n\n<p>† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>",
            "vaccination. Two RCTs performed in patients initiating TNFi versus placebo demonstrated similar responses to influenza vaccination in the 2 arms Rituximab For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due. For patients with RMD receiving rituximab, deferring non-live attenuated vaccinations, other than influenza vaccination, until the next"
        ]
    },
    {
        "pregunta": "9. Why might non-rheumatology providers be encouraged to administer influenza vaccination even if methotrexate is not held immediately?",
        "respuesta": "Se podría alentar a los proveedores no especializados en reumatología (como pediatras generales o internistas) a administrar la vacuna contra la influenza incluso si no se interrumpe inmediatamente el metotrexato para evitar perder la oportunidad de vacunar al paciente. Esto se basa en que asegurar la vacunación oportuna es prioritario, y la suspensión de metotrexato, cuando se hace, debe valorarse individualmente según la actividad de la enfermedad y en consulta con el reumatólogo. Por tanto, la recomendación enfatiza no retrasar ni omitir la vacunación por la posible necesidad de modificar el tratamiento inmunosupresor.",
        "contexto": [
            "<ul>\n<li>Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</li>\n</ul>\n\n<p>† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>",
            "<p>*Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</p>\n\n<p>**Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>",
            "around the time of influenza vaccination is conditionally recommended. For patients with RMD, continuing immunosuppressive medications around the time of other (non-influenza) nonlive attenuated vaccinations is conditionally recommended. Many observational studies The literature review identified no studies that directly addressed the impact of holding medications other than methotrexate at the time of influenza vaccination. Two RCTs performed in patients initiating TNFi versus placebo",
            "medication at the time of non-live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare (Table 3 Methotrexate For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended. For",
            "regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no"
        ]
    },
    {
        "pregunta": "10. What are the vaccination recommendations for patients with RMD taking prednisone at doses ≤10 mg daily?",
        "respuesta": "Para pacientes con enfermedades reumáticas y musculoesqueléticas (ERM) que están tomando prednisona en dosis **iguales o inferiores a 10 mg diarios (equivalente)**, se **recomienda fuertemente administrar cualquier vacuna no viva atenuada**. \n\nEsta recomendación se basa en la evidencia que indica que la inmunogenicidad y eficacia de dichas vacunas son aceptables a estas dosis bajas de glucocorticoides, y el beneficio de la vacunación en estos pacientes supera los riesgos potenciales.",
        "contexto": [
            "| For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non–live attenuated vaccinations is strongly recommended. |                                                  |                                                                                                                      |                          |",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone &gt;10 mg daily but &lt;20 mg daily, administering any non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non–live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as",
            "but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally",
            "<p>† For patients taking the equivalent of prednisone &lt;20 mg/day or &lt;2 mg/kg/day for patients weighing &lt;10 kg or alternate-day glucocorticoid therapy (i.e., “low-level immunosuppression” [15,68]), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency when the patient is not taking glucocorticoids is high.</p>"
        ]
    },
    {
        "pregunta": "11. How should methotrexate dosing be managed around the time of vaccination?",
        "respuesta": "Alrededor del momento de la vacunación con vacunas no vivas atenuadas, se **recomienda condicionalmente suspender metotrexato durante 2 semanas después de la vacunación para la influenza**, asumiendo que la actividad de la enfermedad lo permite.  \n\nPara otras vacunas no vivas atenuadas, se puede **continuar con metotrexato sin suspensión**.  \n\nAdemás, si la dosis de metotrexato es baja (≤0.4 mg/kg/semana) y la vacunación es crítica, con alto riesgo de brote si se suspende el medicamento, el tiempo de suspensión puede acortarse.\n\nEn resumen:  \n- **Vacuna antigripal:** suspender metotrexato 2 semanas después si la actividad de la enfermedad lo permite.  \n- **Otras vacunas no vivas:** continuar metotrexato sin cambios.  \n- **Dosis bajas de metotrexato:** posible reducción del tiempo de suspensión si es necesario.  \n\nEsta estrategia busca maximizar la respuesta inmunitaria a la vacuna, minimizando el riesgo de brotes de la enfermedad reumática.",
        "contexto": [
            "| For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. |                                                  |                                                                                                                      |                          |",
            "<p>‡ For patients taking methotrexate≤0.4 mg/kg/week or azathioprine ≤3 mg/kg/day (“low-level immunosuppression” [15,68]), hold times can be shortened if vaccination is critical and the risk of a disease flare when the patient is not taking immunosuppression is high.</p>",
            "<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>",
            "<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Methotrexate|Hold methotrexate for 2 weeks after vaccination<em>|Continue methotrexate|\n|Rituximab|Continue rituximab</em>*|Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination|\n|Immunosuppressive medications other than methotrexate and rituximab|Continue immunosuppressive medication|Continue immunosuppressive medication|</p>",
            "is preferred, despite moderate evidence suggesting superior efficacy of subcutaneous injections, due to the ease of oral administration and similar bioavailability at typical starting doses Initiation/titration of methotrexate to a weekly dose of at least 15 mg within 4 to 6 weeks is conditionally recommended over initiation/ titration to a weekly dose of <15 mg The recommendation is conditional because there are few studies comparing different dosing strategies and wide variation in physician"
        ]
    },
    {
        "pregunta": "12. What vaccines are classified as non-live attenuated vaccines suitable for patients on immunosuppressive therapy?",
        "respuesta": "La información proporcionada no especifica una lista concreta o clasificación detallada de cuáles vacunas se consideran **no vivas atenuadas** ni cuáles son adecuadas específicamente para pacientes bajo tratamiento inmunosupresor.\n\nSolo se menciona que las vacunas **no vivas atenuadas** pueden administrarse en pacientes con enfermedades reumáticas bajo tratamiento inmunosupresor y que para dosis de prednisona ≤10 mg/día se recomienda fuertemente administrar cualquier vacuna no viva atenuada. También se indica que en general, no se recomienda interrumpir la mayoría de los inmunosupresores (excepto metotrexato y rituximab) alrededor del momento de la vacunación con vacunas no vivas.\n\n**En resumen:**  \nNo hay información disponible en los datos proporcionados para enumerar o clasificar cuáles vacunas son no vivas atenuadas. Se sabe que estas vacunas son consideradas seguras para pacientes que reciben tratamiento inmunosupresor y que se recomienda su administración especialmente en dosis bajas de glucocorticoides.\n\nPara una lista específica y detallada, se debe consultar fuentes especializadas adicionales.",
        "contexto": [
            "<p>| <strong>Immunosuppressive</strong>                                                                                                       | <strong>Non-Immunosuppressive</strong>                                                                                            | <strong>Non-live attenuated</strong>",
            "<h1>Table 4. Whether to give or defer non–live attenuated vaccinations that can be safely given to RMD patients taking immunosuppressive medication.</h1>",
            "<p>|                               | <strong>Influenza vaccination</strong>    | <strong>Other non–live attenuated vaccinations</strong> |\n|-------------------------------|------------------------------|--------------------------------------------|\n| <strong>Prednisone ≤10 mg daily<em></strong>   | ++ Give                         |  ++Give                                       |",
            "<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>",
            "<h1>Table 1. Medication management at the time of non-live attenuated vaccine administration</h1>"
        ]
    },
    {
        "pregunta": "13. What is the conditional recommendation for influenza vaccination in patients taking prednisone ≥20 mg daily?",
        "respuesta": "La recomendación condicional respecto a la vacunación contra la influenza en pacientes con enfermedades reumáticas y musculoesqueléticas (ERM) que están tomando prednisona en dosis iguales o superiores a **20 mg diarios** es **administrar la vacuna antigripal**, a pesar de la dosis alta de glucocorticoides.  \n\nEs decir, se sugiere administrar la vacuna contra la influenza en estos pacientes (prednisona ≥20 mg/día), reconociendo que la inmunogenicidad puede estar reducida, pero considerando que el beneficio de vacunar es mayor que el riesgo de no hacerlo.\n\nPor otro lado, para otras vacunas no vivas atenuadas diferentes a la influenza, se recomienda condicionalmente **posponer su administración hasta que la dosis de glucocorticoides se reduzca a menos de 20 mg/día**.\n\nEn resumen:  \n- **Vacunación influenza en prednisona ≥20 mg/día:** recomendación condicional de administrar.  \n- **Otras vacunas no vivas:** posponer hasta prednisona <20 mg/día.\n\nEsta estrategia busca maximizar la protección frente a la influenza en pacientes con elevado riesgo, incluso bajo dosis altas de glucocorticoides.",
        "contexto": [
            "are tapered to the equivalent of prednisone <20 mg daily is conditionally recommended. Most studies that have compared prednisone <10 mg daily to prednisone ≥10 mg daily found that the higher dosages did reduce influenza vaccine immunogenicity Given the importance of timely influenza vaccination, a conditional recommendation was made to administer influenza vaccination to patients receiving the equivalent of prednisone ≥20 mg daily. For vaccines other than for influenza, a conditional",
            "but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally",
            "| <strong>For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>",
            "<p>† For patients taking the equivalent of prednisone &lt;20 mg/day or &lt;2 mg/kg/day for patients weighing &lt;10 kg or alternate-day glucocorticoid therapy (i.e., “low-level immunosuppression” [15,68]), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency when the patient is not taking glucocorticoids is high.</p>"
        ]
    },
    {
        "pregunta": "14. In what way can intravenous immunoglobulin (IVIG) therapy impact the efficacy of live attenuated vaccines?",
        "respuesta": "La terapia con inmunoglobulina intravenosa (IVIG) puede disminuir la eficacia de las vacunas vivas atenuadas porque los anticuerpos antivirales presentes en la IVIG interfieren con la replicación del virus atenuado de la vacuna. Esta interferencia reduce la respuesta inmunitaria que genera la vacuna. Por ello, se recomienda suspender o evitar la administración de IVIG en un periodo previo a la vacunación para mejorar la eficacia de la vacuna, aunque esta recomendación está orientada a optimizar la respuesta inmunológica y no por motivos de seguridad.",
        "contexto": [
            "the study participant lacked prevaccination immunity to VZV Intravenous immunoglobulin (IVIG). Antiviral antibodies contained in IVIG can interfere with replication of live attenuated vaccines and reduce their efficacy Specific recommendations for holding medications if live attenuated vaccines are given. Although the evidence around the safety of conventional DMARDs and TNFi at the time of live attenuated virus vaccination is reassuring, the total number of RMD patients who have been studied",
            "held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero",
            "<h1>The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efﬁcacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</h1>\n\n<h1>Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*</h1>",
            "<p>d. In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical.</p>\n\n<p>e. the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</p>",
            "attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended. Influenza vaccine responses are greater when the vaccine is administered later rather than earlier after rituximab Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or with active disease (Table 4 Glucocorticoids Whether to administer non-live attenuated"
        ]
    },
    {
        "pregunta": "15. What role do bDMARDs (biologic DMARDs) play in modifying vaccine response or safety profiles?",
        "respuesta": "La información proporcionada no contiene datos específicos sobre el papel que tienen los medicamentos biológicos modificadores de la enfermedad (bDMARDs) en la modificación de la respuesta vacunal ni en los perfiles de seguridad de las vacunas en pacientes con enfermedades reumáticas y musculoesqueléticas.\n\nEn general, se indica que para la vacunación en pacientes bajo tratamiento inmunosupresor (que incluye bDMARDs), la mayoría de los inmunosupresores distintos a metotrexato y rituximab no requieren suspensión alrededor del momento de la vacunación con vacunas no vivas atenuadas, pero no se especifica el impacto particular de los bDMARDs en la inmunogenicidad o seguridad vacunal.\n\nPor lo tanto, **no hay información suficiente en la evidencia disponible para describir cómo los bDMARDs afectan la respuesta inmunitaria a las vacunas ni su perfil de seguridad en este contexto**.",
        "contexto": [
            "|Biologic disease-modifying antirheumatic drugs|Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol); other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)|\n|Glucocorticoids|Oral (any); intravenous (any); intraarticular (triamcinolone acetonide, triamcinolone hexacetonide)|</p>",
            "further research is needed are as follows: 1) standardization of trial design and outcome measures to test the efficacy and durability of response to all vaccines across all age groups; 2) safety of primary and booster live attenuated virus vaccination in children taking methotrexate and/or biologic DMARDs; 3) assessment of the immunogenicity, reactogenicity, and disease flares following standard-dose, high-dose, and adjuvanted influenza vaccination, recombinant VZV vaccination, and primary and",
            "DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be",
            "controlled trials to provide clearer answers to the important questions addressed in the guideline. Data concerning traditional synthetic DMARDs should be updated with randomized controlled trials, and data regarding perioperative management of biologics also needs more definitive study. Patients with rheumatic diseases have higher rates of concomitant metabolic syndrome and cardiac disease and may also be at potentially higher risk of perioperative cardiac and/or thromboembolic events.",
            "<li>MMR = measles, mumps, and rubella (vaccine); PPSV23 = pneumococcal polysaccharide vaccine; PCV13 = pneumococcal conjugate vaccine; csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; IVIG = intravenous immunoglobulin; IBD = inflammatory bowel disease; bDMARDs = biologic DMARDs; TNF = tumor necrosis factor; IL-6R = interleukin-6 receptor; BLyS = B lymphocyte stimulator; tsDMARDs = targeted synthetic DMARDs; CNS = central nervous system; anti-GBM = anti–glomerular"
        ]
    },
    {
        "pregunta": "16. Why is a 4-week hold period recommended before vaccination for patients on slow-acting conventional DMARDs?",
        "respuesta": "Se recomienda un periodo de suspensión de **4 semanas antes de la vacunación con vacunas vivas atenuadas** en pacientes que están en tratamiento con fármacos modificadores de la enfermedad (FAMEs) convencionales de acción lenta (como metotrexato, azatioprina, leflunomida, micofenolato, inhibidores de calcineurina y ciclofosfamida oral) para reflejar su **prolongada duración de acción**.  \n\nEste tiempo busca reducir el nivel de inmunosupresión al momento de la vacunación para mejorar la seguridad y la eficacia de la misma. Sin embargo, se señala que **no existe evidencia directa precisa que determine el tiempo óptimo de suspensión**, por lo que esta recomendación es condicional, basada en la farmacocinética y experiencias clínicas.  \n\nAdemás, en casos donde la vacunación es crítica y el riesgo de brote al suspender el fármaco es alto, este tiempo de suspensión puede acortarse, especialmente para dosis bajas de metotrexato o azatioprina.\n\nEn resumen:  \n- **4 semanas de suspensión antes de la vacuna viva atenuada** en pacientes con FAMEs convencionales de acción lenta se recomienda para compensar su acción prolongada.  \n- La recomendación es condicional debido a la falta de evidencia directa.  \n- Se puede ajustar el tiempo en función de la gravedad de la enfermedad y el riesgo de flare.",
        "contexto": [
            "be found in Table 5 For slow-acting conventional DMARDs, a prevaccination hold time of 4 weeks was chosen to reflect their prolonged duration of action. However, direct evidence for the optimal hold time is lacking. For most biologic DMARDs, a hold time of 1 dosing interval before live attenuated vaccine administration is recommended. The number of RMD patients who are taking immunosuppressive medications at the time that they need live attenuated virus vaccines is small. However, very young",
            "<p>|Immunosuppressive medication|Hold before live-attenuated virus vaccine administration|Hold after live-attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoidsᵃ|4 weeks|4 weeks|\n|Methotrexate, azathioprineᵇ|4 weeks|4 weeks|\n|Leflunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL17, IL12/23, IL23, BAFF/BLyS inhibitors|1 dosing intervalᶜ|4 weeks|",
            "| <strong>For patients with RMD, holding immunosuppressive medication for an appropriate period before and 4 weeks after live attenuated virus vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 24. Should patients with RMD taking drug Y hold the drug for a period of time prior to or after receiving live attenuated vaccines? | 960–964                  |",
            "<p>| |Hold before live attenuated virus vaccine administration|Hold after live attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoids†|4 weeks|4 weeks|\n|Methotrexate, azathioprine‡|4 weeks|4 weeks|\n|Leﬂunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL-17, IL-12/23, IL-23, BAFF/BLyS inhibitors|1 dosing interval§|4 weeks|\n|IL-6 pathway inhibitors|1 dosing interval¶|4 weeks|",
            "<p>‡ For patients taking methotrexate≤0.4 mg/kg/week or azathioprine ≤3 mg/kg/day (“low-level immunosuppression” [15,68]), hold times can be shortened if vaccination is critical and the risk of a disease flare when the patient is not taking immunosuppression is high.</p>"
        ]
    },
    {
        "pregunta": "17. How should vaccination be approached in patients receiving prednisone doses between >10 mg and <20 mg daily?",
        "respuesta": "Para pacientes con enfermedades reumáticas y musculoesqueléticas (ERM) que reciben prednisona en dosis **mayores de 10 mg y menores de 20 mg diarios**, la recomendación es **administrar** tanto la vacunación contra la influenza como otras vacunas no vivas atenuadas, de forma **condicional**.\n\nEs decir, se recomienda dar las vacunas en este rango de dosis glucocorticoidea, con un nivel de recomendación condicional, considerando el balance entre la protección vacunal y la posible reducción de la inmunogenicidad, así como el riesgo de brotes o efectos adversos.",
        "contexto": [
            "are tapered to the equivalent of prednisone <20 mg daily is conditionally recommended. Most studies that have compared prednisone <10 mg daily to prednisone ≥10 mg daily found that the higher dosages did reduce influenza vaccine immunogenicity Given the importance of timely influenza vaccination, a conditional recommendation was made to administer influenza vaccination to patients receiving the equivalent of prednisone ≥20 mg daily. For vaccines other than for influenza, a conditional",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>",
            "<p>† For patients taking the equivalent of prednisone &lt;20 mg/day or &lt;2 mg/kg/day for patients weighing &lt;10 kg or alternate-day glucocorticoid therapy (i.e., “low-level immunosuppression” [15,68]), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency when the patient is not taking glucocorticoids is high.</p>",
            "but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally",
            "| For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non–live attenuated vaccinations is strongly recommended. |                                                  |                                                                                                                      |                          |"
        ]
    },
    {
        "pregunta": "18. How do the hold times differ for medications with more than one FDA-approved dosing interval?",
        "respuesta": "Los medicamentos que tienen más de un intervalo de dosificación aprobado por la FDA deben suspenderse antes de la vacunación (u otra intervención) tomando como referencia **el intervalo de dosificación más largo aprobado**.  \n\nPor ejemplo, en el caso de **adalimumab subcutáneo**, que puede administrarse cada 1 o cada 2 semanas, se recomienda suspenderlo **durante 2 semanas antes** de la administración de la vacuna viva atenuada.  \n\nEn resumen, cuando un medicamento tiene múltiples intervalos de dosificación aprobados, se debe elegir el **intervalo más largo** para determinar el tiempo de suspensión previo (y también posterior) a la vacunación o procedimiento, para garantizar un período adecuado sin el fármaco y minimizar riesgos.",
        "contexto": [
            "<p>§ For medications with &gt;1 dosing interval approved by the Food and Drug Administration, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks, although it can be dosed every 1 or every 2 weeks).</p>",
            "<p>| <strong>Medication</strong>                              | <strong>Dosing Interval</strong>                           | <strong>Recommended Timing of Surgery Since Last Medication Dose</strong> |\n|---------------------------------------------|----------------------------------------------|--------------------------------------------------------------|",
            "<h1>Table 2. Medications included in this 2022 guideline update*</h1>",
            "is critical and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks). d In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated",
            "<p>| |Hold before live attenuated virus vaccine administration|Hold after live attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoids†|4 weeks|4 weeks|\n|Methotrexate, azathioprine‡|4 weeks|4 weeks|\n|Leﬂunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL-17, IL-12/23, IL-23, BAFF/BLyS inhibitors|1 dosing interval§|4 weeks|\n|IL-6 pathway inhibitors|1 dosing interval¶|4 weeks|"
        ]
    },
    {
        "pregunta": "19. What does the guideline suggest about administering multiple vaccines on the same day to RMD patients?",
        "respuesta": "La guía del American College of Rheumatology (ACR) de 2022 **condicionalmente recomienda administrar múltiples vacunas el mismo día en pacientes con enfermedades reumáticas y musculoesqueléticas (ERM)**, en lugar de espaciar cada vacuna en días diferentes. \n\nEsta práctica está respaldada por el CDC y es habitual tanto en medicina pediátrica como adulta, con el objetivo de evitar la pérdida de oportunidades de vacunación. La recomendación se realiza con un nivel condicional, considerando el riesgo individual del paciente y la posibilidad de manejo de medicamentos inmunosupresores alrededor del momento de vacunación.\n\nEn resumen:  \n- Se sugiere condicionalmente administrar varias vacunas simultáneamente en pacientes con ERM.  \n- Evita pérdidas en la adherencia a la vacunación y mejora protección.  \n- Se debe aplicar con evaluación individual y decisión compartida.",
        "contexto": [
            "| <strong>Whether to give multiple vaccinations to patients with RMD on the same day</strong>         |                                                  |                                                                                                                      |                          |</p>",
            "2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases      D064A5AD64D848FEC553AA8136BD6112 10.1002/acr.25045  Conclusion: Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.",
            "Revised February 24, 2023 Whether to give multiple vaccinations to RMD patients on the same day For RMD patients, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended. Medication management at the time of non-live attenuated vaccine administration   Immunosuppressive medication management at the time of live-attenuated virus vaccine administration For RMD patients who are on immunosuppressive medication,",
            "2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases  American College of Rheumatology      263B6488AC287683F9490992215EE324 10.1002/acr.25045 Submitted for publication August 8, 2022; accepted in revised form October 13, 2022.  INTRODUCTION Rheumatic and musculoskeletal diseases (RMDs) 1 2 Avacopan and bimekizumab, the pneumococcal vaccines PCV15 and PCV20, and the smallpox/monkeypox vaccine were not included in the formal",
            "Whether to give multiple vaccinations to patients with RMD on the same day. For patients with RMD, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended. Administering >1 vaccination on a single day is a routine practice in both pediatric and adult medicine that is supported by the CDC in order to avoid a missed vaccination opportunity A summary of the guideline recommendations, associated PICO questions, and"
        ]
    },
    {
        "pregunta": "20. What are the key differences between live attenuated and non-live vaccines regarding their use in immunocompromised patients?",
        "respuesta": "Las diferencias clave entre las vacunas **vivas atenuadas** y las **no vivas** en cuanto a su uso en pacientes inmunocomprometidos (como aquellos con enfermedades reumáticas y musculoesqueléticas bajo tratamiento inmunosupresor) según la información disponible son:\n\n1. **Vacunas vivas atenuadas:**\n   - Contienen un microorganismo vivo debilitado que puede replicarse en el huésped.\n   - Requieren precauciones importantes en pacientes inmunocomprometidos debido a un riesgo potencial de enfermedad vacunal grave por replicación del virus o bacteria atenuada.\n   - Generalmente se recomienda suspender los medicamentos inmunosupresores con acción prolongada semanas antes de la vacunación para reducir el riesgo (por ejemplo, 4 semanas antes para fármacos de acción lenta).\n   - La administración de IVIG (inmunoglobulina intravenosa) antes de la vacunación puede interferir con la eficacia blockeando la replicación viral.\n   - La vacunación debe planificarse cuidadosamente, valorando riesgos de brote por suspensión de inmunosupresores.\n   - En pacientes con alto riesgo de brote o enfermedad activa, se puede considerar acortar los tiempos de suspensión.\n   - No se recomienda administrar vacunas vivas atenuadas en pacientes con inmunosupresión significativa sin ajuste previo.\n\n2. **Vacunas no vivas (inactivadas o subunidades):**\n   - No contienen microorganismos vivos, por lo que no pueden replicarse ni provocar infección en el huésped.\n   - Son consideradas seguras y recomendadas para pacientes immunocomprometidos, incluso aquellos bajo terapia inmunosupresora.\n   - En general, no se requiere suspender la mayoría de fármacos inmunosupresores (excepto metotrexato y rituximab en ciertos casos) durante la administración de vacunas no vivas.\n   - Se administran independientemente del nivel de actividad de la enfermedad o dosis de glucocorticoides, con recomendaciones específicas según dosis (por ejemplo, prednisona ≤10 mg/día).\n   - Su eficacia puede verse reducida por la inmunosupresión, pero el beneficio de la vacunación supera el riesgo.\n   - Las vacunas de alta dosis o con adyuvantes para influenza se recomiendan condicionalmente en pacientes inmunosuprimidos para mejorar la respuesta inmunitaria.\n\nEn resumen:\n\n| Aspecto                                | Vacunas vivas atenuadas                      | Vacunas no vivas                                      |\n|---------------------------------------|----------------------------------------------|-------------------------------------------------------|\n| Contenido                            | Microorganismos vivos debilitados             | Microorganismos inactivados o subunidades             |\n| Riesgo en inmunocomprometidos       | Riesgo significativo de infección vacunal     | Sin riesgo de infección vacunal                         |\n| Manejo de inmunosupresores          | Suspensión previa recomendada (1-4 semanas)   | Generalmente no se requiere suspensión excepto casos específicos (MTX, rituximab) |\n| Seguridad                           | Precaución estricta, no recomendadas en inmunosupresión severa | Consideradas seguras                                   |\n| Eficacia                          | Puede verse afectada por inmunosupresión y IVIG | Puede ser disminuida por inmunosupresión, pero se recomienda |\n| Uso durante brote o actividad alta | Generalmente no recomendadas                    | Se pueden administrar (vaccinación de influenza incluso en actividad alta o con glucocorticoides altas) |\n\nLa administración de vacunas en pacientes inmunocomprometidos debe siempre individualizarse, valorando el estado inmunológico, la actividad de la enfermedad y la terapia inmunosupresora, buscando maximizar beneficios y minimizar riesgos.",
        "contexto": [
            "<p>| <strong>Immunosuppressive</strong>                                                                                                       | <strong>Non-Immunosuppressive</strong>                                                                                            | <strong>Non-live attenuated</strong>",
            "<h1>Table 4. Whether to give or defer non–live attenuated vaccinations that can be safely given to RMD patients taking immunosuppressive medication.</h1>",
            "<h1>Table 1. Medication management at the time of non-live attenuated vaccine administration</h1>",
            "| <strong>Managing immunosuppressive therapy at the time of live attenuated vaccination to avoid vaccine‐associated illness</strong> | <strong>Very low</strong>                                     | PICO 23. Should patients with RMD taking drug Y receive live attenuated vaccines?                                     | 952–960                  |",
            "<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>"
        ]
    }
]